23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Oruka Therapeutics, Inc. › 2025-2026

Oruka Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Oruka Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 211Asset managers, any item
  • 910Fund votes
  • June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 4 items on Oruka Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 2 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 2.3%, as of September 30, 2026)

Explore Oruka Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Oruka Therapeutics, Inc.

These tallies are Oruka Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Oruka Therapeutics, Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Lawrence Klein 43,918,579---- 63,5931,267,194 99.9%Elected—
Elect Director: Chris Martin 43,936,173---- 45,9991,267,194 99.9%Elected—
2. Ratification of Independent Auditor Appointment 45,206,29739,6373,432 ---- 99.9%Approved—
3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis 43,033,967875,11473,091 --1,267,194 98%Approved—

Source: Oruka Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Oruka Therapeutics, Inc. 2025-2026 meeting

211 asset managers disclosed a vote on at least one Oruka Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Chris Martin

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 43,936,173WITHHELD: 45,999
Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2029: Chris Martin

Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Chris Martin”): 43,936,173 for, 45,999 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 54 asset managers voting on “Election of Class II Directors for terms expiring in 2029: Chris Martin” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,975,9580 00For
Vanguard2,187,1000 00For
BlackRock1,157,7260 00For
State Street709,4230 00For
FRANKLIN STRATEGIC SERIES405,2970 00For
Charles Schwab322,1030 00For
T. Rowe Price308,8280 00For
HARBOR FUNDS140,8400 00For
Equitable95,1320 00For
TIAA82,9620 00For
American Century74,0670 00For
Lincoln Financial52,9570 00For
JPMorgan52,5980 00For
ALPS ETF Trust33,0550 00For
Russell Investments31,7800 00For
AIG/SunAmerica29,9670 00For
QUANTITATIVE MASTER SERIES LLC27,0000 00For
Voya24,4530 00For
Brighthouse23,0420 00For
John Hancock19,6200 00For
Global X18,0170 00For
Northern Trust17,8960 00For
Bridge Builder Trust17,5430 00For
Pacific Life15,0260 00For
Advisor Managed Portfolios13,4420 00For

Fund voting reports, all 54 managers: 12,956,798 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class II Directors for terms expiring in 2029: Chris Martin” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,565,6610 00For

Institutional-manager reports, all 1 managers: 1,565,661 for.

Elect Director: Lawrence Klein

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 43,918,579WITHHELD: 63,593
Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2029: Lawrence Klein

Oruka Therapeutics, Inc.’s own tally for this item (“Elect Director: Lawrence Klein”): 43,918,579 for, 63,593 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected each of the two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their successors are elected and have qualified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 54 asset managers voting on “Election of Class II Directors for terms expiring in 2029: Lawrence Klein” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,975,9580 00For
Vanguard2,187,1000 00For
BlackRock1,157,7260 00For
State Street709,4230 00For
FRANKLIN STRATEGIC SERIES405,2970 00For
Charles Schwab322,1030 00For
T. Rowe Price308,8280 00For
HARBOR FUNDS140,8400 00For
Equitable95,1320 00For
TIAA82,9620 00For
American Century74,0670 00For
Lincoln Financial52,9570 00For
JPMorgan52,5980 00For
ALPS ETF Trust33,0550 00For
Russell Investments31,7800 00For
AIG/SunAmerica29,9670 00For
QUANTITATIVE MASTER SERIES LLC27,0000 00For
Voya24,4530 00For
Brighthouse23,0420 00For
John Hancock19,6200 00For
Global X18,0170 00For
Northern Trust17,8960 00For
Bridge Builder Trust17,5430 00For
Pacific Life15,0260 00For
Advisor Managed Portfolios13,4420 00For

Fund voting reports, all 54 managers: 12,953,666 for, 3,132 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Class II Directors for terms expiring in 2029: Lawrence Klein” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,565,6610 00For

Institutional-manager reports, all 1 managers: 1,565,661 for.

Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 43,033,967AGAINST: 875,114
Details: description as filed, official tally, votes by 209 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

Oruka Therapeutics, Inc.’s own tally for this item (“3. Approval of the Compensation of our Named Executive Officers on a Non-Binding, Advisory Basis”): 43,033,967 for, 875,114 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, by non-binding advisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Oruka Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 437 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,975,9580 00For
Vanguard2,187,0991 00For
BlackRock1,157,7260 00For
State Street709,134289 00For
FRANKLIN STRATEGIC SERIES405,2970 00For
Charles Schwab322,1030 00For
T. Rowe Price308,8280 00For
HARBOR FUNDS140,8400 00For
Equitable95,1320 00For
TIAA82,9620 00For
American Century074,067 00Against
Lincoln Financial52,9570 00For
JPMorgan52,5980 00For
ALPS ETF Trust33,0550 00For
Russell Investments31,7800 00For
AIG/SunAmerica29,9670 00For
QUANTITATIVE MASTER SERIES LLC27,0000 00For
Voya24,4530 00For
Brighthouse23,0420 00For
John Hancock19,6200 00For
Global X18,0170 00For
Northern Trust17,8960 00For
Bridge Builder Trust17,5430 00For
Pacific Life15,0260 00For
Advisor Managed Portfolios13,4420 00For

Fund voting reports, all 57 managers: 12,907,356 for, 77,241 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 166 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity7,367,7130 00For
Venrock Adviser, LLC4,180,9070 00For
Fairmount Funds Management LLC3,705,2620 00For
VIKING GLOBAL INVESTORS LP2,666,6900 00For
RTW INVESTMENTS, LP2,052,6060 00For
Deep Track Capital, LP2,019,2030 00For
Polar Capital Holdings Plc1,981,6960 00For
Remedium Capital Partners, LLC1,565,6610 00For
State Street1,331,8194,713 00For
PERCEPTIVE ADVISORS LLC1,076,8290 00For
GEODE CAPITAL MANAGEMENT, LLC931,3580 00For
FRANKLIN ADVISERS INC914,2960 00For
BlackRock873,04514,795 00For
Avidity Partners Management LP760,4240 00For
T. Rowe Price482,2880 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.479,0280 00For
SR ONE CAPITAL MANAGEMENT, LP430,3300 00For
Candriam S.C.A.0411,006 00Against
Holocene Advisors, LP376,1540 00For
Paradigm Biocapital Advisors LP370,5900 00For
GREAT POINT PARTNERS LLC366,6600 00For
Charles Schwab322,1060 00For
Vanguard299,7270 00For
WESTFIELD CAPITAL MANAGEMENT CO LP258,4272,233 00For
PICTET ASSET MANAGEMENT SA202,1060 00For

Institutional-manager reports, all 166 managers: 37,177,262 for, 752,125 against, 221 abstained, 92,796 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Auditor Appointment

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 45,206,297AGAINST: 39,637
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2026.

Oruka Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Auditor Appointment”): 45,206,297 for, 39,637 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm o” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,975,9580 00For
Vanguard2,187,1000 00For
BlackRock1,157,7260 00For
State Street709,4230 00For
FRANKLIN STRATEGIC SERIES405,2970 00For
Charles Schwab322,1030 00For
T. Rowe Price308,8280 00For
HARBOR FUNDS140,8400 00For
Equitable95,1320 00For
TIAA82,9620 00For
American Century74,0670 00For
Lincoln Financial52,9570 00For
JPMorgan52,5980 00For
ALPS ETF Trust33,0550 00For
Russell Investments31,7800 00For
AIG/SunAmerica29,9670 00For
QUANTITATIVE MASTER SERIES LLC27,0000 00For
Voya24,4530 00For
Brighthouse23,0420 00For
John Hancock19,6200 00For
Global X18,0170 00For
Northern Trust17,8960 00For
Bridge Builder Trust17,5430 00For
Pacific Life15,0260 00For
Advisor Managed Portfolios13,4420 00For

Fund voting reports, all 57 managers: 12,984,597 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm o” at Oruka Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Remedium Capital Partners, LLC1,565,6610 00For

Institutional-manager reports, all 1 managers: 1,565,661 for.

Largest Oruka Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 50,167,623 shares outstanding at the time of that meeting.

Fund voting reports: top Oruka Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 13.91%
2Vanguard 4.36%
3BlackRock 2.31%
4State Street 1.41%
5FRANKLIN STRATEGIC SERIES 0.81%
6Charles Schwab 0.64%
7T. Rowe Price 0.62%
8HARBOR FUNDS 0.28%
9Equitable 0.19%
10TIAA 0.17%
Institutional-manager reports: top Oruka Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.69%
2Venrock Adviser, LLC 8.33%
3Fairmount Funds Management LLC 7.39%
4VIKING GLOBAL INVESTORS LP 5.32%
5RTW INVESTMENTS, LP 4.09%
6Deep Track Capital, LP 4.02%
7Polar Capital Holdings Plc 3.95%
8Remedium Capital Partners, LLC 3.12%
9State Street 2.66%
10PERCEPTIVE ADVISORS LLC 2.15%

Reported Oruka Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Oruka Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Fairmount Funds Management LLC14,553,895 —Schedule 13D, filed July 1, 2026
Entities affiliated with Fairmount Funds Management LLC11,162,741 —Proxy statement (DEF 14A), proxy filed April 17, 2026
Peter Harwin11,162,741 —Proxy statement (DEF 14A), proxy filed April 17, 2026
FMR (Fidelity)7,431,403 —Form 13F, quarter ended March 31, 2026
FMR LLC7,261,384 —Proxy statement (DEF 14A), proxy filed April 17, 2026
Entities affiliated with Venrock Healthcare Capital Partners4,909,619 —Proxy statement (DEF 14A), proxy filed April 17, 2026
Venrock Healthcare Capital Partners III, L.P.4,556,952 —Schedule 13G, filed August 14, 2026
BlackRock3,527,087 —Form 13F, quarter ended March 31, 2026
Capital World Investors3,401,639 —Schedule 13G, filed August 12, 2026
Entities affiliated with BlackRock, Inc.3,175,483 —Proxy statement (DEF 14A), proxy filed April 17, 2026

Percentages above are of 50,167,623 shares outstanding, as reported by Oruka Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Oruka Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 211 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 910 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — Oruka Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Oruka Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Oruka Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Oruka Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Oruka Therapeutics (ORKA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/oruka-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.